Maprotiline is a tricyclic antidepressant.
1,2 It binds to the norepinephrine transporter (NET; K
d = 11 nM) and is selective for NET over the serotonin (5-HT) and dopamine transporters (K
ds = 5,800 and 1,000 nM, respectively).
2 Maprotiline also binds to the 5-HT receptor subtype 5-HT
2A (K
I = 51 nM), as well as histamine H
1, muscarinic acetylcholine, α
1-adrenergic, and dopamine D
2 receptors (K
ds = 2, 570, 90, and 350 nM, respectively).
3 In vivo, maprotiline inhibits norepinephrine reuptake in rat brain and peripheral tissues.
4 It reduces isolation-induced aggressive behavior and inhibits electrical foot-shock stimulation-induced belligerence in mice when administered at doses ranging from 3 to 10 mg/kg. Maprotiline (20 μM) prevents acid sphingomyelinase activation and subsequent ceramide release induced by infection with replication-deficient vesicular stomatitis virus pseudoviral particles (pp-VSV) presenting the severe acute respiratory coronavirus 2 (SARS-CoV-2) spike protein in Vero cells, an effect that can be overcome with exogenous application of C16 ceramide (Item No.
10681).
5 Formulations containing maprotiline have been used in the treatment of depression and anxiety. This product is also available as an analytical reference material (Item Nos.
32702 |
33077).